Universal access to quality healthcare and medical innovation remains a global challenge. To address this challenge, many of the world’s top relief and aid organizations have joined together with an ambitious goal: ending the HIV/AIDS pandemic.
As the leading provider of HIV viral load testing, Roche created the Global Access Program to contribute to the UNAIDS 90-90-90 goal, expanding access to quality, sustainable diagnostic testing for countries hardest hit by HIV.
President Bill Clinton, Chairman of the Clinton Health Access Initiative
Michel Sidibé, UNAIDS Executive Director
Redefine the reach of reliable testing. The cobas® Plasma Separation Card makes reliable, quantitative HIV testing more accessible to those in the remote areas. 1
Uncover the impact of accessible HIV diagnostics.
Dried plasma spot testing makes reliable HIV diagnostics more accessible than ever.
The Global Access Program is aiming to make a measurable impact on global HIV numbers.
*Adults and children estimated to be living with HIV in 2014 and 2020, assuming infection rates remain the same.
The Global Access Program contributes to the goals of 90-90-90 by providing diagnostic products for early infant diagnosis and viral load testing.
Early diagnosis in infants and young children is a major challenge—antibody tests are ineffective due to maternal antibodies remaining in the child. The Roche HIV Qualitative assay provides reliable, accurate information on whether or not an infant is infected.5
The use of dried blood spots is an increasingly sustainable solution which allows for PCR testing. Collecting small blood on a specially designed collection card facilitates easy sample transportation and storage, and is ideal for resource-limited areas.5
Roche is a global market leader in HIV viral load testing, a method for determining the amount of HIV circulating in a body. Testing for viral load can confirm if patients are responding to medication, or if second-line therapies should be considered.